Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CGG101
- Development stage
- Preclinical
- Lead developer
- Cure Genetics
- Modality
- Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
CGG101 is an investigational gene therapy being developed by Suzhou Cure Genetics (CureGenetics) for the treatment of cardiovascular diseases. The program utilizes the company's proprietary Virus-like Exosome-Like Particle (VELP) delivery platform, which is a hybrid system designed to combine the high transduction efficiency of viral vectors with the low immunogenicity and biocompatibility of exosomes. This approach aims to facilitate targeted delivery of genetic payloads to cardiovascular tissues while minimizing off-target effects and immune-mediated clearance. Currently in the preclinical stage, CGG101 represents an application of CureGenetics' delivery technology to address unmet needs in cardiovascular medicine.
Beyond the preview
Go deeper on CGG101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CGG101.